HRAS and cancer: In contrast, loss of PIP5K1A either had no effect or even increased the number of viable cells in all but one (TYKNU) of the HRAS-mutant or NRAS-mutant human cancer cell lines, and even in this one cell line, the effect was blunted (Fig. 7a, b).